- Home
- RCS vs PALI Comparison
RCS vs PALI Comparison
Compare RCS & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$1.14
Company Overview
Basic Information| Metric | RCS | PALI |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.4M | 249.2M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RCS | PALI |
|---|---|---|
| Price | $5.01 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 133.7K | ★ 3.1M |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $4.84 | $1.08 |
| 52 Week High | $7.17 | $2.86 |
Technical Indicators
Market Signals| Indicator | RCS | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 35.55 |
| Support Level | $4.87 | N/A |
| Resistance Level | $5.67 | $2.18 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 57.14 | 18.75 |
Price Performance
Historical Comparison RCS
PALI
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with their objective.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.